questionsmedicales.fr
Tumeurs
Tumeurs par type histologique
Leucémies
Leucémies : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neoplasm Recurrence, Local
Diagnostic
5
Leucémie
Biopsie
Analyse sanguine
Hémogramme
Cytométrie en flux
Tests génétiques
Globules blancs
Anémie
Plaquettes
Radiographie
IRM
Extension de la maladie
Biopsie médullaire
Cellules leucémiques
Moelle osseuse
Symptômes
5
Fatigue
Fièvre
Infections
Perte de poids
Symptômes
Leucémie
Système immunitaire
Infections
Leucémie
Douleurs osseuses
Cellules leucémiques
Leucémie
Sueurs nocturnes
Symptômes
Leucémie
Prévention
5
Prévention
Facteurs de risque
Leucémie
Facteurs de risque
Radiations
Maladies génétiques
Tabagisme
Risque
Leucémie
Infections virales
Virus d'Epstein-Barr
Leucémie
Alimentation
Prévention
Santé générale
Traitements
5
Chimiothérapie
Radiothérapie
Greffe de moelle osseuse
Chimiothérapie
Types de leucémie
Efficacité
Greffe de moelle osseuse
Cellules souches
Traitement
Effets secondaires
Chimiothérapie
Nausées
Radiothérapie
Traitement
Complications
Complications
5
Complications
Infections
Saignements
Coagulation sanguine
Saignements
Leucémie
Problèmes cardiaques
Traitements
Leucémie
Infections
Système immunitaire
Leucémie
Douleurs chroniques
Traitements
Leucémie
Facteurs de risque
5
Facteurs de risque
Radiations
Antécédents familiaux
Troubles génétiques
Syndrome de Down
Risque
Antécédents
Chimiothérapie
Risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Leucémies : Questions médicales les plus fréquentes",
"headline": "Leucémies : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Leucémies : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Leucémies"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs par type histologique",
"url": "https://questionsmedicales.fr/mesh/D009370",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs par type histologique",
"code": {
"@type": "MedicalCode",
"code": "D009370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie myéloïde",
"alternateName": "Leukemia, Myeloid",
"url": "https://questionsmedicales.fr/mesh/D007951",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D007951",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myéloïde",
"alternateName": "Leukemia, Myeloid, Acute",
"url": "https://questionsmedicales.fr/mesh/D015470",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D015470",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myélomonocytaire",
"alternateName": "Leukemia, Myelomonocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015479",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myélomonocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.520"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Leucémies",
"alternateName": "Leukemia",
"code": {
"@type": "MedicalCode",
"code": "D007938",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kumaran Mudaliar",
"url": "https://questionsmedicales.fr/author/Kumaran%20Mudaliar",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Laboratory Medicine Loyola University Medical Center Maywood Illinois USA."
}
},
{
"@type": "Person",
"name": "Gregor Eisenwort",
"url": "https://questionsmedicales.fr/author/Gregor%20Eisenwort",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Irina Sadovnik",
"url": "https://questionsmedicales.fr/author/Irina%20Sadovnik",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Alexandra Keller",
"url": "https://questionsmedicales.fr/author/Alexandra%20Keller",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Daniela Berger",
"url": "https://questionsmedicales.fr/author/Daniela%20Berger",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.",
"datePublished": "2022-11-13",
"url": "https://questionsmedicales.fr/article/36371582",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12760-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of local therapy for recurrent pancreatic cancer.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35641368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pan.2022.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultrasound Assessment of Skin Tumors Local Recurrence.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jum.16255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37442715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36371607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14839"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Leucémies",
"item": "https://questionsmedicales.fr/mesh/D007938"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Leucémies - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Leucémies",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Leucémies",
"description": "Comment diagnostique-t-on une leucémie ?\nQuels tests sont utilisés pour confirmer une leucémie ?\nQuels signes indiquent une leucémie lors des tests ?\nLes examens d'imagerie sont-ils nécessaires ?\nQuelle est l'importance de la biopsie médullaire ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Neoplasm+Recurrence,+Local#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Leucémies",
"description": "Quels sont les symptômes courants de la leucémie ?\nLa perte de poids est-elle un symptôme de leucémie ?\nComment la leucémie affecte-t-elle le système immunitaire ?\nLes douleurs osseuses sont-elles liées à la leucémie ?\nLes sueurs nocturnes sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Neoplasm+Recurrence,+Local#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Leucémies",
"description": "Peut-on prévenir la leucémie ?\nQuels facteurs de risque sont associés à la leucémie ?\nLe tabagisme augmente-t-il le risque de leucémie ?\nLes infections virales peuvent-elles causer la leucémie ?\nL'alimentation joue-t-elle un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Neoplasm+Recurrence,+Local#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Leucémies",
"description": "Quels sont les traitements principaux de la leucémie ?\nLa chimiothérapie est-elle efficace contre toutes les leucémies ?\nQu'est-ce qu'une greffe de moelle osseuse ?\nQuels sont les effets secondaires de la chimiothérapie ?\nLa radiothérapie est-elle utilisée pour traiter la leucémie ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Neoplasm+Recurrence,+Local#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Leucémies",
"description": "Quelles sont les complications possibles de la leucémie ?\nComment la leucémie affecte-t-elle la coagulation sanguine ?\nLes leucémies peuvent-elles entraîner des problèmes cardiaques ?\nQuelles infections sont fréquentes chez les patients leucémiques ?\nLes leucémies peuvent-elles causer des douleurs chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Neoplasm+Recurrence,+Local#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Leucémies",
"description": "Quels sont les principaux facteurs de risque de leucémie ?\nL'âge influence-t-il le risque de leucémie ?\nLes troubles génétiques augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de leucémie ?\nLes antécédents de chimiothérapie augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Neoplasm+Recurrence,+Local#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une leucémie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, une biopsie de moelle osseuse et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une leucémie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'hémogramme, la cytométrie en flux et les tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une leucémie lors des tests ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des globules blancs, une anémie et des plaquettes basses peuvent indiquer une leucémie."
}
},
{
"@type": "Question",
"name": "Les examens d'imagerie sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens comme la radiographie ou l'IRM peuvent aider à évaluer l'extension de la maladie."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la biopsie médullaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie médullaire permet d'évaluer la présence de cellules leucémiques dans la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la leucémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, infections fréquentes et saignements faciles."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle un symptôme de leucémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut être un symptôme de leucémie."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie affaiblit le système immunitaire, rendant le corps plus vulnérable aux infections."
}
},
{
"@type": "Question",
"name": "Les douleurs osseuses sont-elles liées à la leucémie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs osseuses peuvent survenir en raison de l'accumulation de cellules leucémiques."
}
},
{
"@type": "Question",
"name": "Les sueurs nocturnes sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les sueurs nocturnes peuvent être un symptôme courant chez les patients leucémiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la leucémie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à la leucémie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition aux radiations, certains produits chimiques et des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque de leucémie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour certains types de leucémie."
}
},
{
"@type": "Question",
"name": "Les infections virales peuvent-elles causer la leucémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, sont liées à un risque accru de leucémie."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut contribuer à la santé générale, mais ne prévient pas spécifiquement la leucémie."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements principaux de la leucémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et la greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace contre toutes les leucémies ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est efficace pour de nombreux types de leucémie, mais pas tous."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une greffe de moelle osseuse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui remplace la moelle osseuse malade par des cellules souches saines."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la chimiothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée pour traiter la leucémie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter certaines leucémies, surtout en cas de complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la leucémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections graves, saignements, et complications liées aux traitements."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle la coagulation sanguine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie peut entraîner des troubles de la coagulation, augmentant le risque de saignements."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles entraîner des problèmes cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements de la leucémie peuvent augmenter le risque de problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quelles infections sont fréquentes chez les patients leucémiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections bactériennes et fongiques sont courantes en raison d'un système immunitaire affaibli."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles causer des douleurs chroniques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs chroniques peuvent survenir en raison de la maladie ou des traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de leucémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'exposition aux radiations, certains produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de leucémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de leucémie augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les troubles génétiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme le syndrome de Down augmentent le risque de leucémie."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque de leucémie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes ont généralement un risque plus élevé de leucémie que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents de chimiothérapie augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir reçu une chimiothérapie pour un autre cancer peut augmenter le risque de leucémie."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
└─
Leucémie myéloïde
Leukemia, Myeloid
D007951 -
C04.557.337.539
└─└─
Leucémie aigüe myéloïde
Leukemia, Myeloid, Acute
D015470 -
C04.557.337.539.275
└─└─
Leucémie aigüe myélomonocytaire
Leukemia, Myelomonocytic, Acute
D015479 -
C04.557.337.539.520
└─└─└─
Leucémie aiguë à basophiles
Leukemia, Basophilic, Acute
D015471 -
C04.557.337.539.275.125
└─└─└─
Leucémie aigüe à éosinophiles
Leukemia, Eosinophilic, Acute
D015472 -
C04.557.337.539.275.300
└─└─└─
Leucémie aigüe mégacaryoblastique
Leukemia, Megakaryoblastic, Acute
D007947 -
C04.557.337.539.275.450
└─└─└─
Leucémie aigüe monoblastique
Leukemia, Monocytic, Acute
D007948 -
C04.557.337.539.275.484
└─└─└─
Leucémie aiguë promyélocytaire
Leukemia, Promyelocytic, Acute
D015473 -
C04.557.337.539.275.700
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR....
This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g...
For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien...
This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...
Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap...
We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c...
A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ...
Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....
Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonme...
Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders...
A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana...
388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ...
A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...
Using CODA, a technique for three-dimensional reconstruction of large tissues, Kiemen et al. report observation of a microscopic focus of pancreatic cancer found in the vasculature of grossly normal h...
The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that...
We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w...
This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ...
The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer...
CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ...
Level III, therapeutic study....
A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca...
Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro...
Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs...
A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...
The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic...
One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ...
HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'...
We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....
This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)....
An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center....
In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,...
Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....
RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ...
Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc...
Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....
